Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling

References

• Ponder BAJ. Cancer genetics. Nature 411(6835), 336–341 (2001).
   PubMedGoogle Scholar
• Liotta LA, Kohn EC. The microenvironment of the tumor—host interface. Nature 411(6835), 375–379 (2001).
   PubMed Web of Science ®Google Scholar
• Minamoto T, Ronai Z. Gene mutation as a target for early detection in cancer diagnosis. Grit. Rev. Onca Hematol. 40(3), 195–213 (2001).
   Google Scholar
• Fearon ER Human cancer syndromes: clues to the origin and nature of cancer. Science 278(5340), 1043–1050 (1997).
   PubMedGoogle Scholar
• Adjei AA. Blocking oncogenic ras signaling for cancer therapy. J. Natl Cancer Inst. 93(14), 1062–1074 (2001).
   PubMed Web of Science ®Google Scholar
• Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas and lung cancers — a review. Cancer Detect. Prey. 24(1), 1–12 (2000).
   Google Scholar
• •Detailed data on the ability of molecular diagnosis of cancer patients and individuals at risk targeting the K-ras oncogene, which are obtained from the respective reports at its publication.
   Google Scholar
• Blume-Jensen R Hunter T Oncogenic kinase signalling. Nature 411(6835), 355–365 (2001).
   Google Scholar
• Wong NA, Pignatelli M. I3-catenin — a linchpin in colorectal carcinogenesis?Am. I Pathol. 160(2), 389–401 (2002).
   Google Scholar
• Miller JR, Hocking AM, Brown JD, Moon RT. Mechanism and function of signal transduction by Wnt/I3-catenin and Wnt/ Ca2+ pathways. Oncogene 18(55), 7860–7872 (1999).
   Google Scholar
• Taipale J, Beachy PA. The hedgehog andWnt signalling pathways in cancer. Nature 411(6835), 349–354(2001).
   PubMed Web of Science ®Google Scholar
• Raj GM Moreno JG, Gomella LG. Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer 82(8), 1419–1442 (1998).
   PubMedGoogle Scholar
• Takayama T, Katsuki S, Takahashi Y et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl. J. Med. 339(18), 1277–1284 (1998).
   Google Scholar
• Takayama T, Ohi M, Hayashi T et al. Analysis of K-ras, APC and 13-catenin in aberrant crypt foci in sporadic adenoma, cancer and familial adenomatous polyposis. Gastroenterology 121(3), 599–611 (2001).
   Google Scholar
• Tada M, Ohashi M, Shiratori Yet al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 110(1), 227–231 (1996).
   PubMed Web of Science ®Google Scholar
• MiOZZO M, Sozzi G, Musso K et al. Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res. 56(10), 2285–2288 (1996).
   Google Scholar
• Polakis P. The oncogenic activation of13- catenin. Curr. Opin. Genet. Dev. 9(1), 15-21(1999).
   Google Scholar
• Korinek V, Barker N, Morin PJ et al. Constitutive transcriptional activation by a I3-catenin—Tcf complex in APC-/- colon carcinoma. Science 275(5307), 1784–1787 (1997).
   Google Scholar
• Morin PJ, Sparks AB, Korinek Vet id Activation of I3-catenin — Tcf signaling in colon cancer by mutations inI3-catenin or APC. Science 275(5307), 1787–1790 (1997).
   Google Scholar
• Willert K, Nusse R I3-catenin: a key mediator of Wnt signaling. Curr. Opin. Genet. Dev. 8(1), 95–102 (1998).
   Google Scholar
• He TC, Sparks AB, Rago C et aZ Identification of c-MYC as a target of the APC pathway. Science 281(5382), 1509–1512 (1998).
   PubMed Web of Science ®Google Scholar
• Tetsu 0, McCormick F. 13-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398(6726), 422–426 (1999).
   Google Scholar
• Mann B, Gelos M, Siedow A et aZ Target genes of I3-catenin —T-cell-factor/lymphoid enhancer factor signaling in human colorectal carcinomas. Proc. Natl Acad. Sci. USA 96(4), 1603–1608 (1999).
   Google Scholar
• Crawford HC, Fingleton BM, Rudolph- Owen LA et al. The metalloproteinase matrilysin is a target of13-catenin transactivation in intestinal tumors. Oncogene 18(18), 2883–2891 (1999).
   Google Scholar
• Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. I3-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol. 155(4), 1033–1038 (1999).
   Google Scholar
• Van Aken E, De Weyer 0, Correia da Rocha AS, Mareel M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch. 439(6), 725–721 (2001)
   Google Scholar
• Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 278(5340), 1054–1059 (1997).
   PubMedGoogle Scholar
• •Provides the fundamentals of molecular diagnosis and its impact on clinical practice
   Google Scholar
• Nakamura Y, Inazawa J. Genetic diagnosis of cancer. Intl. Clin. OricoZ 3,265–270 (1998).
   Google Scholar
• Ponder B. Genetic testing for cancer risk. Science 278(5340), 1050–1054 (1997).
   PubMedGoogle Scholar
• Perera FP. Environment and cancer: who are susceptible? Science 278(5340), 1068–1073 (1997).
   Google Scholar
• Minamoto T, Mai M, Ronai Z. Environmental factors as regulators and effectors of multistep carcinogenesis. Carcinogenesis 20(4), 519–527 (1999).
   PubMedGoogle Scholar
• Wu JS, Fazio VW Colon cancer.Dis. Colon Rectum 43(11), 1473–1486 (2000).
   PubMedGoogle Scholar
• Muto T, Kotake K, Koyama Y. Colorectal cancer statistics in Japan: data from JSCCR registration, 1974–1993. Int.j Clin. Oncol. 6(4), 171–176 (2001).
   Google Scholar
• Rex DK, Rahmani EY, Haseman JH et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 112(1), 17–23 (1997).
   PubMed Web of Science ®Google Scholar
• Agrez MV, Coory M, Cockburn J. Population screening for colorectal carcinoma with fecal-occult blood testing: are we sufficiently informed? Cancer 82(10), 1803–1807 (1998).
   Google Scholar
• Burt RW Colon cancer screening. Gastroenterology 119(3), 837–853 (2000).
   Google Scholar
• Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 119(3), 854–865 (2000).
   PubMed Web of Science ®Google Scholar
• Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W Kirchner T. Nuclear overexpression of the oncoprotein 0-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract. 194(10), 701–704 (1998).
   Google Scholar
• Gunther K, Brabletz T, Kraus Get al. Predictive value of nuclear 13-catenin expression for the occurrence of distant metastases in rectal cancer. Dis. Colon Rectum 41(10), 1256–1261 (1998).
   Google Scholar
• Hugh TJ, Dillon SA, O'Dowd G et aZ 0- catenin expression in primary and metastatic colorectal carcinoma. Int. J. Cancer 82(4), 504-511(1999).
   Google Scholar
• Maruyama K, Ochiai A, Akimoto S et al. Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology 59(4), 302–309 (2000).
   PubMedGoogle Scholar
• Brabletz T, Jung A, Reu S et al. Variable I3-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl Acad. Sci. USA 98(18), 10356–10361 (2001).
   Google Scholar
• Ougolkov A, Yamashita K, Mai M, Minamoto T. Oncogenic13-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 122(1), 60-71(2002).
   Google Scholar
• •First report showing distinct patterns of oncogenic P-catenin activation in clinical colon cancer and their prevalence in and impact on molecular diagnosis of cancer patients.
   Google Scholar
• Miyaki M, Iijima T, Kimura J et al. Frequent mutation of P-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res. 59(18), 4506–4509 (1999).
   Google Scholar
• Mirabelli-Primdahl L, Gryfe R, Kim H et al. I3-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res. 59(14), 3346–3351 (1999).
   Google Scholar
• Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 349(9050), 485–489 (1997).
   PubMedGoogle Scholar
• Sener SF, Fremgen A, Menk HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100313 patients diagnosed from 1985–1995, using the National Cancer Database. J. Am. Coll. Sing. 189(1), 1–7 (1999).
   Google Scholar
• Matsuno S, Egawa S, Shibuya K et al. Pancreatic cancer: current status of treatment and survival of 16071 patients diagnosed from 1981–1996, using the Japanese National Pancreatic Cancer Database. Int. J. Clin. Oncol. 5(3), 153–157 (2000).
   Google Scholar
• Adamek HE, Albert J, Breer H, Weitz M, Schilling D, Riemann F. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 356(9225), 190–193 (2000).
   PubMed Web of Science ®Google Scholar
• Gerdes B, Ramaswamy A, Simon B et al. Analysis of13-catenin gene mutations in pancreatic tumors. Digestion 60(6), 544 548 (1999).
   Google Scholar
• Tanaka Y, Kato K, Notohara K et aZ Frequent 13-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res. 61(23), 8401–8404 (2001).
   Google Scholar
• Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer Clin. 50(1), 7–33 (2000).
   Google Scholar
• Mountain CE Revisions in the international staging system for lung cancer. Chest 111(6), 1710–1717 (1997).
   Google Scholar
• Hirsch FR, Franklin WA, Gazder AF, Bunn PA Jr. Early detection in lung cancer: clinical perspectives of recent advances in biology and radiology. Clin. Cancer Res. 7(1), 5–22 (2001).
   Google Scholar
• Shibanuma H, Hirano T, Tsuji K et al. Influence of E-cadherin dysfunction upon local invasion and metastasis in non-small cell lung cancer. Lung Cancer 22(2), 85–95 (1998).
   PubMedGoogle Scholar
• Nawrocki B, Polette M, Van Hengel J, Tournier J-M, Van Roy F, Birembault Cytoplasmic redistribution of E-cadherin—catenin adhesion complex is associated with downregulated tyrosine phosphorylation of E-cadherin in human bronchopulmonary carcinomas. Am.j Pathol. 153(5), 1521–1530 (1998).
   Google Scholar
• Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K Expression of E-cadherin and13-catenin in human non-small cell lung cancer and the clinical significance. Clin. Cancer Res. 6(12), 4789–4796 (2000).
   Google Scholar
• Hommura F, Furuuchi K, Yamazaki K et al. Increased expression of I3-catenin predicts better prognosis in non-small cell lung cancer. Cancer 94(3), 752–758 (2002).
   Google Scholar
• Bremnes RM, Veve R, Hirsch FR, Franklin WA. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis and prognosis. Lung Cancer 36(2), 115–124 (2002).
   PubMed Web of Science ®Google Scholar
• Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 18(1), 65–73 (1999).
   Google Scholar
• Kopreski MS, Benko FA, Kwee C et Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br. J. Cancer 76(10), 1293–1299 (1997).
   Google Scholar
• Anker P, Lefort F, Vasioukhin V et al.K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 112(4), 1114–1120 (1997).
   PubMed Web of Science ®Google Scholar
• Hibi K, Robinson CR, Booker S et al. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res. 58(7), 1405–1407 (1998).
   Google Scholar
• Kopreski MS, Benko FA, Bogs DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J. Natl Cancer Inst. 92(11), 918–923 (2000)
   PubMedGoogle Scholar
• ••Original article that best demonstrates aparadigm of molecular diagnosis targeting K-ras oncogene through a well-organized, prospective study that subjects plasma DNA samples.
   Google Scholar
• Mulcahy HE, Lyautey J, Ledderey C et al. A prospective study of K-ras mutation in the plasma of pancreatic cancer patients. Clin. Cancer Res. 4(2), 271–275 (1998).
   PubMedGoogle Scholar
• Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60(7), 1777–1788 (2000).
   Google Scholar
• Chen XQ Stroun M, Magnenat JL et aZ Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nature Med. 2(9), 1033–1035 (1996).
   Google Scholar
• Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Med. 2(9), 1035–1037 (1996).
   PubMed Web of Science ®Google Scholar
• Goessl C, Heicappell R, Munker R et aZ Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res. 58(20), 4728–4732 (1998).
   Google Scholar
• Esteller M, Sanchez-Cespedes M, Rosen R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59(1), 67–70 (1999).
   Google Scholar
• Wong IH, In YM, Zhang J et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59(1), 71–73 (1999).
   Google Scholar
• Silva J, Dominguez G, Villanueva Metal. Aberrant DNA methylation of the p 16I1VK4a gene in plasma of breast cancer patients. Br. J. Cancer 80(8), 1262–1264 (1999).
   Google Scholar
• Sanchez-Cespedes M, Esteller M, Wu L et aZ Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60(4), 892–895 (2000).
   Google Scholar
• Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLF/1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 61(3), 900–902 (2001).
   Google Scholar
• Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 61(8), 3225–3229 (2001)
   Google Scholar
• ••Promising target for a new strategy ofmolecular diagnosis of human cancers. A series of promoter hypermethylation in a dozen of genes that play critical roles in tumor development and progression are analysed in DNA from over 600 tumor samples representing 15 major tumor types.
   Google Scholar
• Tornberg SA. Screening for early detection of cancer—ethical aspects. Acta Oncol. 38(1), 77–81(1999).
   Google Scholar